TGA backs NeuroScientific stem cell assault on Crohn’s disease

NeuroScientific has received approval from Australia’s drug regulator to treat its first patients with Crohn’s disease using its “StemSmart” stem cell therapy, in a major step towards a phase two trial in 2026.